MA39250A1 - Protéines hybrides de l'interleukine-2 et leurs utilisations - Google Patents

Protéines hybrides de l'interleukine-2 et leurs utilisations

Info

Publication number
MA39250A1
MA39250A1 MA39250A MA39250A MA39250A1 MA 39250 A1 MA39250 A1 MA 39250A1 MA 39250 A MA39250 A MA 39250A MA 39250 A MA39250 A MA 39250A MA 39250 A1 MA39250 A1 MA 39250A1
Authority
MA
Morocco
Prior art keywords
proteins
relates
hybrid
interleukin
hybrid proteins
Prior art date
Application number
MA39250A
Other languages
English (en)
Other versions
MA39250B1 (fr
Inventor
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Christian Klein
Laurence Bernard Peterson
Linda Wicker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA39250A1 publication Critical patent/MA39250A1/fr
Publication of MA39250B1 publication Critical patent/MA39250B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de manière générale des protéines hybrides d'immunoglobulines et de l'interleukine-2 (il -2). Elle concerne plus particulièrement des protéines hybrides d'immunoglobulines et d'il-2 mutante, qui présentent des propriétés améliorées permettant de les utiliser comme agents thérapeutiques, par exemple dans le traitement de maladies auto-immunes et des maladies inflammatoires à médiation immunitaire. Elle concerne en outre des polynucléotides codant pour ces protéines hybrides, ainsi que des vecteurs et des cellules hôtes comprenant ces polynucléotides. L'invention concerne également des méthodes de production des protéines hybrides de l'invention, et des méthodes d'utilisation des celles-ci dans le traitement de maladies.
MA39250A 2014-02-06 2015-02-04 Protéines hybrides de l'interleukine-2 et leurs utilisations MA39250B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936564P 2014-02-06 2014-02-06
PCT/EP2015/052312 WO2015118016A1 (fr) 2014-02-06 2015-02-04 Protéines hybrides de l'interleukine-2 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA39250A1 true MA39250A1 (fr) 2018-03-30
MA39250B1 MA39250B1 (fr) 2018-09-28

Family

ID=52669578

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39250A MA39250B1 (fr) 2014-02-06 2015-02-04 Protéines hybrides de l'interleukine-2 et leurs utilisations

Country Status (32)

Country Link
US (1) US11098099B2 (fr)
EP (2) EP3508496A1 (fr)
JP (2) JP6306201B2 (fr)
KR (2) KR20190126205A (fr)
CN (2) CN111423513A (fr)
AR (1) AR099289A1 (fr)
AU (2) AU2015215001B2 (fr)
BR (1) BR112016018288A2 (fr)
CA (1) CA2931114A1 (fr)
CL (1) CL2016001968A1 (fr)
CR (1) CR20160333A (fr)
DK (1) DK3102595T3 (fr)
EA (2) EA201992609A1 (fr)
ES (1) ES2704731T3 (fr)
HR (1) HRP20190028T1 (fr)
HU (1) HUE041530T2 (fr)
IL (1) IL245484B (fr)
LT (1) LT3102595T (fr)
MA (1) MA39250B1 (fr)
MX (2) MX370283B (fr)
NZ (2) NZ760289A (fr)
PE (1) PE20161324A1 (fr)
PH (1) PH12016501406B1 (fr)
PL (1) PL3102595T3 (fr)
PT (1) PT3102595T (fr)
RS (1) RS58149B1 (fr)
SG (1) SG11201606369XA (fr)
SI (1) SI3102595T1 (fr)
TW (1) TWI671318B (fr)
UA (1) UA120847C2 (fr)
WO (1) WO2015118016A1 (fr)
ZA (1) ZA201603262B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
RS62421B1 (sr) 2014-12-05 2021-10-29 Aragon Pharmaceuticals Inc Anti-kancerogeni sastavi
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
JP7292877B2 (ja) * 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3263595A1 (fr) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Protéine de fusion pour une utilisation dans le traitement de maladie hvg
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
JP7213180B2 (ja) 2016-10-19 2023-01-26 エフ．ホフマン－ラ ロシュ アーゲー 免疫コンジュゲートを製造するための方法
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
EP3538548A4 (fr) * 2016-11-08 2020-08-19 Delinia, Inc. Variants d'il-2 pour le traitement de maladies auto-immunes
CN110177564A (zh) * 2016-12-13 2019-08-27 德里尼亚公司 多价的调节t细胞调节剂
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
JOP20190271A1 (ar) * 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US11780899B2 (en) 2017-12-06 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to IL-2
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3752178A1 (fr) 2018-02-16 2020-12-23 Iltoo Pharma Utilisation de l'interleukine 2 pour traiter le syndrome de sjögren
EP3765517A1 (fr) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles se liant à calréticuline et utilisations associees
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
AU2019288496B2 (en) 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
WO2020007937A1 (fr) 2018-07-03 2020-01-09 Iltoo Pharma Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique
WO2020010250A2 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
EP3836954B1 (fr) 2018-08-13 2025-05-07 Iltoo Pharma Combinaison d'interleukine-2 avec un inhibiteur de l'interleukine 1, conjugués et leurs utilisations thérapeutiques
CN112105634B (zh) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
CA3098930A1 (fr) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Nouvelle interleukine 2 et utilisation associee
CN113924311A (zh) * 2019-01-07 2022-01-11 印希比股份有限公司 包含修饰的il-2多肽的多肽及其用途
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
CN119350468A (zh) * 2019-03-29 2025-01-24 居里研究所 具有经修饰的生物活性的白介素-2变体
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス， インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
WO2020252421A2 (fr) * 2019-06-14 2020-12-17 Cugene, Inc. Nouveaux variants d'interleukine-2 et leurs molécules de fusion bifonctionnelles
KR20260089650A (ko) * 2019-07-12 2026-06-15 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CN114555634B (zh) 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
IL293978A (en) * 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
WO2021138474A2 (fr) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
IL295143B2 (en) 2020-02-13 2026-02-01 Hoffmann La Roche A method for determining the loading state of AAV particles using nuclear magnetic resonance relaxometry
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021185362A1 (fr) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 Mutant de l'interleukine-2 et son utilisation
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
CN113912735B (zh) * 2020-07-08 2025-03-28 南京师范大学 多肽二聚体及其用途
KR20230060514A (ko) * 2020-09-01 2023-05-04 다케다 야쿠힌 고교 가부시키가이샤 인터루킨-2 뮤테인 및 이의 용도
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
US20240325495A1 (en) 2020-10-29 2024-10-03 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
KR20230117122A (ko) * 2020-12-04 2023-08-07 에프. 호프만-라 로슈 아게 pH 의존성 돌연변이체 인터류킨-2 폴리펩티드
CA3203977A1 (fr) 2020-12-04 2022-06-09 Visterra, Inc. Procedes d'utilisation d'agents d'interleukine-2
WO2022179970A1 (fr) 2021-02-24 2022-09-01 F. Hoffmann-La Roche Ag Régénération et utilisation multiple de filtres en profondeur
CN115232215B (zh) * 2021-04-23 2026-03-27 湖州芈首生物技术有限公司 一种融合蛋白ABD/Fc/IL-2及其编码基因、制备方法和应用
WO2022245500A1 (fr) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Polypeptides d'il-21 et constructions ciblées
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
CN113789346A (zh) * 2021-08-25 2021-12-14 北京伟德杰生物科技有限公司 长效化重组人白细胞介素2融合蛋白及其制备方法和应用
CN118414160A (zh) * 2021-10-06 2024-07-30 艾尔图制药公司 对发炎组织具有靶向特异性的白介素2嵌合构建体
GB202115122D0 (en) * 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
AU2022477937A1 (en) 2022-09-12 2025-04-10 Assistance Publique - Hôpitaux De Paris Interleukin-2 for use in treating autism spectrum disorder
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808353C2 (de) 1977-04-18 1984-01-19 Hitachi Metals, Ltd., Tokyo Ohrring
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1985000817A1 (fr) 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
EP1454138B1 (fr) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines a selectivite modulee
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
WO2005007121A2 (fr) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Polypeptides de l'interleukine-2(il-2) mutante
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2005100402A1 (fr) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anticorps anti-p-selectine
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
MX2007006234A (es) 2004-11-24 2007-07-20 Schering Corp Dap10, y usos de la misma.
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
US8119130B2 (en) 2007-07-25 2012-02-21 Medimmune Limited Targeted binding agents directed to KDR and uses thereof—035
WO2009061853A2 (fr) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Polypeptides d'interleukine-2 (il-2) mutants
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
WO2010085495A1 (fr) * 2009-01-21 2010-07-29 Amgen Inc. Compositions et procédés de traitement de maladies inflammatoires et auto-immunes
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
EP3443979B2 (fr) 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris Régime posologique d'il-2 pour le traitement du lupus érythémateux systémique
LT2691417T (lt) * 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US11492383B2 (en) * 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
CN105980410A (zh) 2016-09-28
CL2016001968A1 (es) 2017-02-24
LT3102595T (lt) 2019-01-25
KR102042246B1 (ko) 2019-11-28
MX2016009687A (es) 2017-03-10
SI3102595T1 (sl) 2019-02-28
CR20160333A (es) 2016-09-05
DK3102595T3 (en) 2019-02-04
NZ760289A (en) 2023-05-26
JP2018102312A (ja) 2018-07-05
BR112016018288A2 (pt) 2017-10-10
KR20160103134A (ko) 2016-08-31
CN111423513A (zh) 2020-07-17
JP2017510551A (ja) 2017-04-13
EP3102595B1 (fr) 2018-11-07
NZ719654A (en) 2020-06-26
EA201992609A1 (ru) 2020-03-04
HRP20190028T1 (hr) 2019-02-22
MX2019014695A (es) 2020-02-07
PE20161324A1 (es) 2016-11-25
UA120847C2 (uk) 2020-02-25
IL245484B (en) 2019-10-31
JP6306201B2 (ja) 2018-04-04
RS58149B1 (sr) 2019-02-28
TW201534625A (zh) 2015-09-16
PL3102595T3 (pl) 2019-04-30
EA034350B1 (ru) 2020-01-30
MX370283B (es) 2019-12-09
EA201691576A1 (ru) 2016-12-30
CA2931114A1 (fr) 2015-08-13
WO2015118016A1 (fr) 2015-08-13
AU2015215001B2 (en) 2019-08-15
US11098099B2 (en) 2021-08-24
IL245484A0 (en) 2016-06-30
PH12016501406A1 (en) 2016-08-31
HUE041530T2 (hu) 2019-05-28
ZA201603262B (en) 2019-10-30
PH12016501406B1 (en) 2022-04-22
AR099289A1 (es) 2016-07-13
KR20190126205A (ko) 2019-11-08
AU2019264579A1 (en) 2019-12-05
PT3102595T (pt) 2019-01-11
EP3102595A1 (fr) 2016-12-14
CN105980410B (zh) 2020-02-28
AU2015215001A1 (en) 2016-05-19
TWI671318B (zh) 2019-09-11
MA39250B1 (fr) 2018-09-28
ES2704731T3 (es) 2019-03-19
EP3508496A1 (fr) 2019-07-10
US20150218260A1 (en) 2015-08-06
SG11201606369XA (en) 2016-09-29

Similar Documents

Publication Publication Date Title
MA39250B1 (fr) Protéines hybrides de l'interleukine-2 et leurs utilisations
MA40510A (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
CY1122956T1 (el) Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471B1 (fr) Compositions comprenant des souches bactériennes
EP4597112A3 (fr) Anticorps anti-galectine-9 et leurs utilisations
MX394103B (es) Anticuerpos anti-angptl8 y usos de estos.
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MX377712B (es) Anticuerpos dirigidos contra il-33 y sus usos.
EP4425179A3 (fr) Compositions et procédés pour fluorescence améliorée
MY171180A (en) Anti-hla-b*27 antibodies and uses thereof
MA41010B1 (fr) Compositions comprenant des souches bactériennes
EP4219724A3 (fr) Compositions et procédés pour traiter une déficience auditive non associée au vieillissement chez un sujet humain
MA35448B1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
WO2017015622A3 (fr) Protéines de liaison à gdf11 et leurs utilisations
EA201891573A1 (ru) Конъюгат терапевтических ферментов
CR20210622A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
MX2015005384A (es) Miembros de union para il-1 beta.
MX2024001617A (es) Composiciones biofarmaceuticas.
MA43773B1 (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
MA38308A1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
CR20200322A (es) Anticuerpos de cadena pesada que se unen a cd22
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
FR3094180B1 (fr) Composition proteique de feverole
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).